<DOC>
	<DOCNO>NCT01995734</DOCNO>
	<brief_summary>The present study plan expand treatment protocol provide acromegalic patient medical therapy appropriate access pasireotide LAR regulatory approval pasireotide seek .</brief_summary>
	<brief_title>An Open-label , Multi-center , Expanded Treatment Protocol Pasireotide LAR Patients With Acromegaly</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<criteria>Patients confirm diagnosis active acromegaly elevate IGF1 ( &gt; ULN ) random GH ( &gt; 1 μg/L ) within 30 day screen . Patients control pituitary surgery eligible refuse surgery . For patient medical treatment acromegaly follow washout period must complete screen assessment perform : Dopamine agonist ( bromocriptine , cabergoline ) : 4 week GHreceptor antagonist ( pegvisomant ) : 8 week Somatostatin analogue : washout period require Karnofsky performance status ≥ 60 . Concomitant treatment somatostatin analogues unless concomitant treatment discontinue 28 day first pasireotide LAR injection administrate . Concomitant treatment growth hormone receptor ( GHR ) antagonists dopamine agonist unless concomitant treatment discontinue washout period complete screening assessment perform . Patients compression optic chiasm cause visual field defect surgical intervention indicate . Patients require surgical intervention relief sign symptom associate tumor compression . Patients undergone major surgery/surgical therapy cause within 4 week screen . Patients receive radiotherapy pituitary within 4 week prior screen recover side effect radiotherapy . Patients history hypothyroidism adequately treat stable dos thyroid hormone replacement therapy . Patients active malignant disease within last five year ( exception basal cell carcinoma carcinoma situ cervix ) . Diabetic patient whose blood glucose poorly control . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Acromegaly , Pituitary disease</keyword>
</DOC>